急性髓系白血病异基因造血干细胞移植后复发的治疗进展
Progress in the treatment of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation
戴纬 1金梦迪 1郭智2
作者信息
- 1. 华中科技大学协和深圳医院血液内科,广东 深圳 518052
- 2. 华中科技大学协和深圳医院血液内科,广东 深圳 518052;国家卫生健康委核技术医学转化实验室(绵阳市中心医院),广东 深圳 518052
- 折叠
摘要
急性髓系白血病异基因造血干细胞移植后复发是移植后死亡的首要原因.移植后复发的治疗暂无统一标准,主流的治疗措施包括二次异基因造血干细胞移植、供者淋巴细胞输注、常规化疗、去甲基化药物的应用、靶向药物治疗、嵌合抗原T细胞疗法(CAR-T)等.本文就急性髓系白血病异基因造血干细胞移植后复发的治疗最新进展做一综述.
Abstract
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia is a major mortality risk.Currently,there is a lack of consensus regarding the optimal treatment for post-transplant relapse,with common strategies including second allogeneic transplantation,donor lymphocyte infusion,conventional chemotherapy,demethylating agents,targeted therapies,and chimeric antigen receptor T cell therapy.This article comprehensively reviewed the progress in the management of recurrence after allogeneic hematopoietic stem cell transplantation.
关键词
急性髓系白血病/异基因造血干细胞移植/复发/治疗进展Key words
acute myeloid leukemia/allogeneic hematopoietic stem cell transplantation/relapse/therapeutic progress引用本文复制引用
出版年
2024
NETL
NSTL
万方数据